1. Home
  2. CXH vs PMVP Comparison

CXH vs PMVP Comparison

Compare CXH & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Investment Grade Municipal Trust

CXH

MFS Investment Grade Municipal Trust

HOLD

Current Price

$8.02

Market Cap

66.4M

Sector

Finance

ML Signal

HOLD

Logo PMV Pharmaceuticals Inc.

PMVP

PMV Pharmaceuticals Inc.

HOLD

Current Price

$1.34

Market Cap

79.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXH
PMVP
Founded
1989
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.4M
79.5M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
CXH
PMVP
Price
$8.02
$1.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.0K
428.6K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.56%
N/A
EPS Growth
N/A
N/A
EPS
0.23
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$34.91
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.34
$0.82
52 Week High
$8.39
$1.88

Technical Indicators

Market Signals
Indicator
CXH
PMVP
Relative Strength Index (RSI) 39.86 45.16
Support Level $7.89 $1.26
Resistance Level $8.04 $1.50
Average True Range (ATR) 0.10 0.06
MACD -0.02 -0.03
Stochastic Oscillator 30.00 28.21

Price Performance

Historical Comparison
CXH
PMVP

About CXH MFS Investment Grade Municipal Trust

Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.

About PMVP PMV Pharmaceuticals Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Share on Social Networks: